GSK: financial statements from SEC — TradeAlmanac

GSK

GSK plc: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Revenue	32.67bn	31.38bn	30.33bn	29.32bn
Cost of revenue	9.02bn	9.05bn	8.57bn	9.55bn
Gross profit	23.65bn	22.33bn	21.76bn	19.77bn
Research and development	7.53bn	6.40bn	6.22bn	5.49bn
Selling, general and administrative	9.09bn	11.02bn	9.39bn	8.37bn
Operating income	7.93bn	4.02bn	6.75bn	6.43bn
Pre-tax income	7.40bn	3.48bn	6.06bn	5.63bn
Income tax	1.11bn	526m	756m	707m
Net income	6.29bn	2.95bn	5.31bn	15.62bn
Earnings per share	1.41	0.63	1.22	3.71
Earnings per share, diluted	1.39	0.62	1.20	3.66

Balance sheet

Metric	Aug 18, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash and equivalents	—	3.40bn	3.87bn	2.94bn	3.72bn	—
Receivables	—	7.47bn	6.84bn	7.39bn	—

Cash flow

Metric	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Operating cash flow	7.74bn	6.55bn	6.77bn	7.40bn
Capital expenditure	1.35bn	1.40bn	1.31bn	1.14bn
Investing cash flow	−4.23bn	−1.23bn	−1.60bn	−8.77bn
Financing cash flow

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)